Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries. This is the fifth major breast cancer…
VENUS REMEDIES ONCOLOGY WING ON EXPANSION SPREE WITH MARKETING APPROVALS FROM FOUR KEY MARKETS
Making rapid strides in the oncology space by expanding its global reach, Venus Remedies Ltd, a well-known provider of affordable cancer drugs worldwide, has further consolidated its position in the Gulf Cooperation Council (GCC), Association of South East Asian Nations…